UPDATE: J.P. Morgan Upgrades Hologic; Raises PT
According to a research report published this morning, J.P. Morgan has upgraded Hologic (NASDAQ: HOLX) from Neutral to Overweight, and increased PT from $20 to $22.
In the report, J.P. Morgan commented, "While we are not constructive on the ultimate returns that are likely to be achieved on the GPRO deal, and we question the top-line outlook for the combined diagnostics segment, we believe that the risk/reward is now too compelling to ignore, in light of the significant potential for cost synergies ($75M+), strong free cash flow generation ($700M+ in 2013E), low probability of further deals in the near term, and now attractive valuation (>15% FCF yield), following a >20% pullback in the stock."
Hologic closed Friday at $17.44.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.